Sign In
19 Jun 2018 07:00
Polarean Imaging Plc
("Polarean" or the "Company")
Investor Symposium
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces it will be holding an Investor Symposium for investors today.
A welcome and introduction will be given by Richard Hullihen, CEO. The morning will also feature presentations by:
· Bastiaan Driehuys, Ph.D., Founder and Chief Technology Officer
HPX Present and Future
· Professor Fergus Gleeson, Clinical Adviser
Clinical Applications at Oxford
· Kenneth West, Chief Operating Officer
FDA Strategy and Clinical Trial
The event will take place at Grace Hall, 147 Leadenhall Street, London, EC3V 4QT at 8.45am for a 9.00am start. This will be followed by light refreshments and a chance to network with all members of the Company's management team in attendance.
The presentations will be available on the Company website shortly after the event, and no new material or trading information will be provided.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email polarean@walbrookpr.com.
Enquiries:
Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | ||
Richard Hullihen, Chief Executive Officer | Via Walbrook PR | ||
Richard Morgan, Chairman | |||
| |||
Northland Capital Partners Limited | Tel: +44 (0)20 3861 6625 | ||
David Hignell / Gerry Beaney / Jamie Spotswood (Corporate Finance) John Howes / Rob Rees (Corporate Broking) | |||
MC Services (European IR) | Tel: +49 (0)89 210 2280 | ||
Raimund Gabriel | |||
The Life Sciences Division (Financial Adviser) | |||
Navid Malik, Director | Mob: 07957 224 730 | ||
Alia Minhas, CEO | Mob: 07590 696 057 | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | ||
Paul McManus / Anna Dunphy Helen Cresswell | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 +44 (0)7841 917 679 | ||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.
The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.
Follow the stocks
